| Subject: | Changes to Prescribing Information for Exjade - Boxed Warning |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 18 Feb 2010 - 12:00 pm |
| Audience: Hematology-Oncology healthcare professionals The Food and Drug Administration (FDA) and Novartis Oncology have notified healthcare professionals about recent changes in the Prescribing Information (PI) for Exjade, indicated for the treatment of chronic iron overload due to blood transfusions in patients two (2) years of age and older. New language was added to the Contraindications, Warnings and Precautions, and Drug Interactions sections of the PI, including a Boxed Warning, that the... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
